Patents by Inventor Ming-Hong Hao

Ming-Hong Hao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210205348
    Abstract: Provided herein are methods for the treatment of bladder cancer.
    Type: Application
    Filed: May 31, 2019
    Publication date: July 8, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-Wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • Publication number: 20210163456
    Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
    Type: Application
    Filed: April 8, 2019
    Publication date: June 3, 2021
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Gregg F. KEANEY, John WANG, Baudouin GERARD, Kenzo ARAI, Xiang LIU, Guo Zhu ZHENG, Kazunobu KIRA, Lisa A. MARCAURELLE, Marta NEVALAINEN, Ming-Hong HAO, Morgan Welzel O'SHEA, Parcharee TIVITMAHAISOON, Sudeep PRAJAPATI, Touping LUO, Nicholas C. GEARHART, Jason T. LOWE, Yoshihiko KOTAKE, Satoshi NAGAO, Regina Mikie KANADA SONOBE, Masayuki MIYANO, Norio MURAI, Andrew COOK, Shelby ELLERY, Atsushi ENDO, James PALACINO, Dominic REYNOLDS
  • Patent number: 10912774
    Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: February 9, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Dominic Reynolds, Ming-Hong Hao, John Wang, Sudeep Prajapati, Takashi Satoh, Anand Selvaraj
  • Patent number: 10851065
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: December 1, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu
  • Publication number: 20200299321
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Application
    Filed: February 4, 2020
    Publication date: September 24, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • Publication number: 20200255415
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Application
    Filed: November 22, 2017
    Publication date: August 13, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu, Lorna Helen Mitchell, Nicholas Larsen, Nathalie Rioux, Sudeep Prajapati, Dominic Reynolds, Morgan O'Shea, Thiwanka Samarakoon
  • Publication number: 20200206222
    Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
    Type: Application
    Filed: December 17, 2019
    Publication date: July 2, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dominic REYNOLDS, Ming-Hong HAO, John WANG, Sudeep PRAJAPATI, Takashi SATOH, Anand SELVARAJ
  • Patent number: 10618930
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: April 14, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • Publication number: 20200055883
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Application
    Filed: February 16, 2018
    Publication date: February 20, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • Patent number: 10537571
    Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 21, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Dominic Reynolds, Ming-Hong Hao, John Wang, Sudeep Prajapati, Takashi Satoh, Anand Selvaraj
  • Publication number: 20190345192
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Application
    Filed: February 15, 2019
    Publication date: November 14, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • Publication number: 20190337921
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Application
    Filed: November 22, 2017
    Publication date: November 7, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu, Lorna Helen Mitchell, Nicholas Larsen, Nathalie Rioux
  • Patent number: 10246480
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: April 2, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-Wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • Publication number: 20180237468
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Application
    Filed: February 17, 2018
    Publication date: August 23, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-Wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • Publication number: 20180141913
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Application
    Filed: November 22, 2017
    Publication date: May 24, 2018
    Applicant: EISAI R & D MANAGEMENT CO., LTD.
    Inventors: Mark BOCK, Ming-Hong HAO, Manav KORPAL, Vijay Kumar NYAVANANDI, Xiaoling PUYANG, Susanta SAMAJDAR, Peter Gerard SMITH, John WANG, Guo Zhu ZHENG, Ping ZHU, Lorna Helen MITCHELL, Nicholas LARSEN, Nathalie RIOUX, Sudeep PRAJAPATI, Dominic REYNOLDS, Morgan O'SHEA, Thiwanka SAMARAKOON
  • Publication number: 20180127378
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Application
    Filed: September 22, 2017
    Publication date: May 10, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Mark BOCK, Ming-Hong HAO, Manav KORPAL, Vijay Kumar NYAVANANDI, Xiaoling PUYANG, Susanta SAMAJDAR, Peter Gerard SMITH, John WANG, Guo Zhu ZHENG, Ping ZHU
  • Publication number: 20170360785
    Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
    Type: Application
    Filed: June 20, 2017
    Publication date: December 21, 2017
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Dominic REYNOLDS, Ming-Hong HAO, John WANG, Sudeep PRAJAPATI, Takashi SATOH, Anand SELVARAJ
  • Patent number: 9796683
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: October 24, 2017
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu
  • Patent number: 9730931
    Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: August 15, 2017
    Assignee: EISAI R&D Management Co., Ltd.
    Inventors: Dominic Reynolds, Ming-Hong Hao, John Wang, Sudeep Prajapati, Takashi Satoh, Anand Selvaraj
  • Publication number: 20170007601
    Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
    Type: Application
    Filed: July 27, 2016
    Publication date: January 12, 2017
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Dominic REYNOLDS, Ming-Hong HAO, John WANG, Sudeep PRAJAPATI, Takashi SATOH, Anand SELVARAJ